VericelNASDAQ: VCEL

CAMBRIDGE, Mass., June 11, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO, and Joe Mara, CFO, will participate in a fireside chat at the Truist Securities MedTech Conference at 2:30 p.m. ET on Tuesday, June 18, 2024.

Vericel Corporation (VCEL) came out with quarterly earnings of $0.26 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.12 per share a year ago.

Does Vericel Corporation (VCEL) have what it takes to be a top stock pick for momentum investors? Let's find out.

If you are looking for stocks that are well positioned to maintain their recent uptrend, Vericel Corporation (VCEL) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

CAMBRIDGE, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President and CEO will present at the Canaccord Genuity Musculoskeletal Conference. The presentation is scheduled to begin at 11:00 a.m. ET (8:00 a.m. PT) on Monday, February 12, 2024.

If you are looking for stocks that are well positioned to maintain their recent uptrend, Vericel Corporation (VCEL) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Vericel Corporation (VCEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Vericel Corporation (NASDAQ:VCEL ) Q3 2023 Earnings Conference Call November 8, 2023 8:30 AM ET Company Participants Eric Burns - Vice President, Finance and Investor Relations Nick Colangelo - President and Chief Executive Officer Joe Mara - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Mike Kratky - Leerink Partners Jeffrey Cohen - Ladenburg Thalmann Samuel Brodovsky - Truist Securities George Sellers - Stephens Inc Arthur He - HCW Operator Ladies and gentlemen, thank you for standing by. Welcome to Vericel's Third Quarter 2023 conference call.

Vericel Corporation demonstrates consistent growth in its core product lines, including MACI for cartilage repair and Epicel for severe burn treatment, with significant competitive advantages and barriers to entry. The company is expanding its market share and exploring new applications for its products, such as MACI for ankle defects, which could increase its total addressable market by $1 billion. Despite some risks, including limited direct competition and potential growth limits, Vericel is well-positioned financially and expected to achieve net profitability within the next 12-18 months.